FDA Approves Merck's First-of-Its-Kind Cholesterol Pill Lipfendra at $10.50 Per Pill

Merck (MRK) has received FDA approval for Lipfendra, a novel daily cholesterol pill that is the first in its class. The drug is expected to be list-priced at $10.50 per pill, according to the company.

The Product

Lipfendra is an oral daily medication belonging to a new class of PCSK9 inhibitors. Unlike existing injectable treatments, Lipfendra is taken as a single daily pill, which may improve patient adherence. Clinical trials showed it can reduce LDL cholesterol by up to 50% in patients who cannot tolerate statins.

Pricing and Availability

The list price is $10.50 per pill, or approximately $315 per month. Merck has not yet announced any patient assistance programs or insurance coverage details. The drug is expected to be available in pharmacies within weeks.

Competition

Lipfendra competes with injectable PCSK9 drugs like Repatha (Amgen) and Praluent (Sanofi/Regeneron), which cost $500–600 per month. It also faces competition from cheap statins. Merck bets on the convenience of a daily pill as a key differentiator.

Potential Impact on Merck

Lipfendra represents a new growth opportunity for Merck in the multibillion-dollar cholesterol market. Success could boost Merck's revenue and reduce its reliance on older products. The challenge lies in securing broad insurance coverage and convincing doctors and patients to switch treatments.